{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:46:30Z","timestamp":1784544390294,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01960-y","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:31:00Z","timestamp":1762338660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Tianxiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihai","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"1","key":"1960_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/PAP.0b013e318204c0cf","volume":"18","author":"GP Paner","year":"2011","unstructured":"Paner GP, Zehnder P, Amin AM, Husain AN, Desai MM. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: A comprehensive review of literature with implications for patient management. Adv Anat Pathol. 2011;18(1):79. https:\/\/doi.org\/10.1097\/PAP.0b013e318204c0cf.","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"1960_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1960_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"EAU Guidelines on Non","year":"2017","unstructured":"EAU Guidelines on Non\u2013Muscle-invasive Urothelial Carcinoma of the Bladder. Update 2016. Eur Urol. 2017;71(3):447\u201361. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041.","journal-title":"Eur Urol"},{"key":"1960_CR4","doi-asserted-by":"publisher","first-page":"102072","DOI":"10.1016\/j.ctrv.2020.102072","volume":"89","author":"M Koufopoulou","year":"2020","unstructured":"Koufopoulou M, Miranda PAP, Kazmierska P, Deshpande S, Gaitonde P. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: current paradigms and emerging treatment options. Cancer Treat Rev. 2020;89:102072. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102072.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"1960_CR5","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer unfit for Cisplatin-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(17):2432\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.34.8433.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"1960_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.euo.2021.02.010","volume":"4","author":"B Szabados","year":"2021","unstructured":"Szabados B, Prendergast A, Jackson-Spence F, Choy J, Powles T. Immune checkpoint inhibitors in Front-line therapy for urothelial cancer. Eur Urol Oncol. 2021;4(6):943\u20137. https:\/\/doi.org\/10.1016\/j.euo.2021.02.010.","journal-title":"Eur Urol Oncol"},{"key":"1960_CR7","doi-asserted-by":"publisher","first-page":"175883592110473","DOI":"10.1177\/17588359211047352","volume":"13","author":"C Stecca","year":"2021","unstructured":"Stecca C, Abdeljalil O, Sridhar SS. Metastatic urothelial cancer: a rapidly changing treatment landscape. Ther Adv Med Oncol. 2021;13:17588359211047352. https:\/\/doi.org\/10.1177\/17588359211047352.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"1960_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40259-023-00606-5","volume":"37","author":"AM Singh","year":"2023","unstructured":"Singh AM, Guevara-Patino JA, Wang X, Li R, Sonpavde G, Jain RK. Antibody-Drug conjugates in the treatment of urothelial cancer. BioDrugs Clin Immunother Biopharm Gene Ther. 2023;37(4):505\u201320. https:\/\/doi.org\/10.1007\/s40259-023-00606-5.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"issue":"6","key":"1960_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11912-024-01524-7","volume":"26","author":"A Ghose","year":"2024","unstructured":"Ghose A, Lapitan P, Apte V, et al. Antibody drug conjugates in urological cancers: A review of the current landscape. Curr Oncol Rep. 2024;26(6):633\u201346. https:\/\/doi.org\/10.1007\/s11912-024-01524-7.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1960_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng X, Yan X, Wang L, et al. Open-label, Multicenter, phase II study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(1):43\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2488.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"15suppl","key":"1960_CR11","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1200\/jco.2021.39.15_suppl.4584","volume":"39","author":"X Sheng","year":"2021","unstructured":"Sheng X, He Z, Han W, et al. An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009). J Clin Oncol. 2021;39(15suppl):4584\u20134584. https:\/\/doi.org\/10.1200\/jco.2021.39.15_suppl.4584.","journal-title":"J Clin Oncol"},{"key":"1960_CR12","doi-asserted-by":"publisher","first-page":"1549647","DOI":"10.3389\/fimmu.2025.1549647","volume":"16","author":"C Zhang","year":"2025","unstructured":"Zhang C, Yu Y, Zhou Q, Ouyang J, Zhang Z. Disitamab Vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: a comparative analysis of efficacy and safety in muscle-invasive bladder cancer. Front Immunol. 2025;16:1549647. https:\/\/doi.org\/10.3389\/fimmu.2025.1549647.","journal-title":"Front Immunol"},{"issue":"1","key":"1960_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12967-025-06237-4","volume":"23","author":"H Ge","year":"2025","unstructured":"Ge H, Liu C, Shen C, et al. The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. J Transl Med. 2025;23(1):243. https:\/\/doi.org\/10.1186\/s12967-025-06237-4.","journal-title":"J Transl Med"},{"key":"1960_CR14","doi-asserted-by":"publisher","unstructured":"Hu H, Guo S, Huang S et al. MP16-09 TRUCE04: A phase ii clinical trial of rc48 for high-risk non-muscle-invasive bladder cancer (HR-NMIBC) (NCT05495724). J Urol. Published online May 2024. https:\/\/doi.org\/10.1097\/01.JU.0001008640.01272.9d.09","DOI":"10.1097\/01.JU.0001008640.01272.9d.09"},{"key":"1960_CR15","doi-asserted-by":"publisher","unstructured":"Yang K, Ji Y, Zhou L, et al. Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab Vedotin plus Toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression. J Clin Oncol Published Online June. 2024;1. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4568.","DOI":"10.1200\/JCO.2024.42.16_suppl.4568"},{"issue":"2","key":"1960_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jncc.2023.02.003","volume":"3","author":"H Lei","year":"2023","unstructured":"Lei H, Ling Y, Yuan P, et al. Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer. J Natl Cancer Cent. 2023;3(2):121\u20138. https:\/\/doi.org\/10.1016\/j.jncc.2023.02.003.","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"1960_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","volume":"29","author":"F Shi","year":"2022","unstructured":"Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022;29(1):1335\u201344. https:\/\/doi.org\/10.1080\/10717544.2022.2069883.","journal-title":"Drug Deliv"},{"key":"1960_CR18","doi-asserted-by":"publisher","first-page":"1432586","DOI":"10.3389\/fimmu.2024.1432586","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Shan K, Huang W, et al. The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer. Front Immunol. 2024;15:1432586. https:\/\/doi.org\/10.3389\/fimmu.2024.1432586.","journal-title":"Front Immunol"},{"issue":"3","key":"1960_CR19","doi-asserted-by":"publisher","first-page":"102093","DOI":"10.1016\/j.clgc.2024.102093","volume":"22","author":"J Chen","year":"2024","unstructured":"Chen J, Wang M, Qi X, et al. RC48-Antibody-Drug conjugate in metastatic urothelial carcinoma: A multicenter Real-World study in China. Clin Genitourin Cancer. 2024;22(3):102093. https:\/\/doi.org\/10.1016\/j.clgc.2024.102093.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"1960_CR20","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/cncr.34057","volume":"128","author":"VS Koshkin","year":"2022","unstructured":"Koshkin VS, Henderson N, James M, et al. Efficacy of enfortumab Vedotin in advanced urothelial cancer: analysis from the urothelial cancer network to investigate therapeutic experiences (UNITE) study. Cancer. 2022;128(6):1194\u2013205. https:\/\/doi.org\/10.1002\/cncr.34057.","journal-title":"Cancer"},{"key":"1960_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.urology.2015.12.007","volume":"89","author":"AO Siefker-Radtke","year":"2016","unstructured":"Siefker-Radtke AO, Campbell MT, Munsell MF, Harris DR, Carolla RL, Pagliaro LC. Front-line treatment with Gemcitabine, Paclitaxel, and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: final results from a phase II study. Urology. 2016;89:83\u20139. https:\/\/doi.org\/10.1016\/j.urology.2015.12.007.","journal-title":"Urology"},{"issue":"12","key":"1960_CR22","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng X, Wang L, He Z, et al. Efficacy and safety of disitamab Vedotin in patients with human epidermal growth factor receptor 2-Positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42(12):1391\u2013402. https:\/\/doi.org\/10.1200\/JCO.22.02912.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"1960_CR23","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg J, Sridhar SS, Zhang J, et al. EV-101: A phase I study of Single-Agent enfortumab Vedotin in patients with Nectin-4-Positive solid Tumors, including metastatic urothelial carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(10):1041\u20139. https:\/\/doi.org\/10.1200\/JCO.19.02044.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"1960_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3760\/cma.j.cn112152-20220713-00489","volume":"45","author":"Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association;, Expert Committee for Monitoring the Clinical Application of Antitumor Drugs;, Breast Cancer Expert Committee of National Cancer Quality Control Center;, Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center","year":"2023","unstructured":"Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association;, Expert Committee for Monitoring the Clinical Application of Antitumor Drugs;, Breast Cancer Expert Committee of National Cancer Quality Control Center;, Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center. [Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)]. Zhonghua Zhong Liu Za Zhi. 2023;45(9):741\u201362. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20220713-00489.","journal-title":"Zhonghua Zhong Liu Za Zhi"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01960-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01960-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01960-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:31:21Z","timestamp":1762338681000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01960-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1960"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01960-y","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board of First Affiliated Hospital of Huzhou University with a waiver of informed consent, as it used anonymized clinical data without additional interventions, complying with the Declaration of Helsinki and local regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}